Major Depressive Disorder (MDD) Clinical Trial
— ENSUREOfficial title:
Emotional Cognition: Establishing Constructs and Neural-Behavioral Mechanisms in Older Adults With Depression (ENSURE; R21 MH130870)
This is a cross-sectional pilot study designed to establish hot and cold cognitive functions and underlying neurocircuitry in older adults with MDD. The investigators will study 60 participants aged 21-80 years old with MDD. All participants will undergo clinical and neurocognitive assessment, and Magnetoencephalography (MEG)/Magnetic resonance imaging (MRI) procedures at one time point. The investigators will also enroll 60 demographically matched comparable, never-depressed healthy participants (controls) to establish cognitive benchmarks. Healthy controls will complete clinical and neurocognitive measures at one time point. To attain a balanced sample of adults across the lifespan, the investigators will enroll participants such that each age epoch (e.g., 21-30, 31-40, etc.) has a total of ten subjects (n=10) in both the healthy control cohort and depressed cohort.
Status | Recruiting |
Enrollment | 138 |
Est. completion date | December 2025 |
Est. primary completion date | November 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Male and female participants 2. Age between 21-80 years old 3. DSM-5 diagnosis of major depressive disorder (MDD) based on Mini Neuropsychiatric Interview 4. Inventory of Depressive Symptomatology-Clinician Rated version (IDS-C) total score > 14 5. Able to read, write, and comprehend English 6. Provide informed consent; willing to comply with study protocol Exclusion Criteria: 1. History of bipolar disorder, schizophrenia, or schizoaffective disorder 2. Presence of psychotic features 3. Lifetime central nervous system (CNS) disease (including head injury with loss of consciousness > 5 minutes) 4. History of neurodevelopmental disorder (e.g., Autism spectrum disorder) 5. History of medical conditions that can affect neurocognitive function as well as be confounded with age (e.g., thyroid disease, endocrine illnesses) 6. History and current use of hormonal replacement therapy 7. Women who are pregnant 8. Current use of medications with known impacts on neurocognitive function (e.g., acetylcholinesterase inhibitors, amphetamine, methylphenidate, vortioxetine, sedatives) 9. Alcohol/substance use disorder within past 3 months 10. DSM-5 diagnosis of major cognitive impairment 11. Current sensory or physical impairment that interferes with testing. 12. Contraindication to MRI and MEG (only for depressed participants) (e.g., any electronic / metallic implants near or within the head or body, claustrophobia) |
Country | Name | City | State |
---|---|---|---|
United States | University of Texas Arlington | Arlington | Texas |
United States | University of Texas Southwestern Medical Center | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas Southwestern Medical Center | National Institute of Mental Health (NIMH), The University of Texas at Arlington |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Emotion Processing Domain: Emotional Intensity Morphing Task | Assesses the point of intensity for fascial emotion recognition. Faces are presented with slowly morphing emotional expressions (e.g., happy, sad, angry) that increases (point of detection) or decrease (emotion no longer perceived).
Intensity threshold for each emotion and each condition (i.e., increases and decrease). |
baseline visit, total time= 5 minutes | |
Primary | Emotion Processing Domain: Emotional Recognition Task-Eyes | Assesses accuracy and affective bias of emotional recognition. Participants identify emotion(e.g., happy, sad) based on 250ms presentation of eyes only.
Hit rate (i.e., correct identification of each emotion). |
baseline visit, total time= 12 minutes | |
Primary | Emotion Processing Domain: Face Affective Go No-Go | Assesses affective bias associated with emotional faces. Participant must identify the target facial emotion (e.g., happy, sad), while ignoring other emotions.
Discrimination accuracy (d-prime score for each emotion). |
baseline visit, total time= 6 minutes | |
Primary | Reward Processing and Learning: Adapted Cambridge Gambling Task | Assesses value-based choice. Participants bet on expected outcomes when presented with a colored (orange, purple) roulette wheel with the proportions of each color indicating 1 of 5 levels of certain/uncertain outcomes in the context of win or loss conditions.
Risk Adjustment scores based on level of probability of win or loss. |
baseline visit, total time= 10 minutes | |
Primary | Reward Processing and Learning: Reinforcement Learning Task | Assesses reward and punishment learning. Participants are shown colored circles and choose the one they believe is more likely to win money. There are two conditions (no lose and no win).
Learning rate (alpha) based on how fast participant learns new information (both win and loss). Risk Adjustment scores based on level of probability of win or loss. |
baseline visit, total time= 10 minutes | |
Primary | Impulsivity: Discounting Task | Assesses rate of discounting across 5 levels of delay and 5 of probability. Participants decide between a standard fixed amount vs an immediately available alternative.
Indifference points for each length of delay/degree of uncertainly, noted by area under the curve. |
baseline visit, total time= 7 minutes | |
Primary | Social Cognition: Moral Emotions Task | Assesses moral judgment/emotional reactions to social situations. Cartoons depict characters intentionally or unintentionally harming one another. Participants rate feelings (e.g., guilt, shame) as either the victim or antagonizer in the scenario.
Average ratings of guilt and shame in each scenario (victim or antagonizer). |
baseline visit, total time= 13 minutes | |
Secondary | Montreal Cognitive Assessment (MoCA): Cold Cognitive Function Testing. | Description: Cold cognitive function will be measured by Montreal Cognitive Assessment (MoCA). MoCA assesses multiple cognitive domains: attention, concentration, executive functions, memory, language, visuospatial skills, abstraction, calculation and orientation. Possible scores range from 0-30, where score = 26 is considered to be normal. | Day 1/baseline | |
Secondary | Everyday Cognition (ECog): Cold Cognitive Function Testing | Cold cognitive function will be measured by Everyday Cognition (ECog), ECog scale is a validated informant-rated questionnaire that includes one global factor and six domain-specific factors: 6 domains: everyday memory, language, visuospatial and perceptual abilities, planning, organization, and divided attention. Each item is scored based on a four-point scale: 1 = better or no change compared to 10 years earlier; 2 =questionable/occasionally worse; 3 = consistently a little worse; 4 = consistently much worse. The total score will be calculated as the sum of all 39 items. Higher scores indicates worse daily function | Day 1 | |
Secondary | Test of Premorbid Function (TOPF): Cold Cognitive Function Testing | Cold cognitive function will be measured by Test of Premorbid Function (TOPF), TOPF estimates an individual's pre-morbid cognitive and memory functioning. Possible scores range from 80 - 130, where higher scores indicate better pre-morbid cognitive functioning. | Day 1 | |
Secondary | California Verbal Learning Test-3 (CVLT-3): Cold Cognitive Function Testing | Cold cognitive function will be measured by California Verbal Learning Test-3 (CVLT-3), CVLT-3 measures verbal learning and memory. Possible scores range from 0 - 16, where higher scores indicate better performance. | Day 1 | |
Secondary | Delis-Kaplan Executive Function System (DKEF)-Color-Word Interference: Cold Cognitive Function Testing | Cold cognitive function will be measured by Delis-Kaplan Executive Function System (D-KEF) Color-Word Interference, it is made up of color naming, word reading, and inhibition, is measured in seconds, a smaller number represents a better outcome. | Day 1 | |
Secondary | Delis-Kaplan Executive Function System (DKEF)-Tower Test: Cold Cognitive Function Testing | Cold cognitive function will be measured by D-KEF Tower test, it is a measure of executive function. Total achievement scores indicate the highest score participants scored on the test. Possible score range from 0 - 30, higher scores indicate better performance. | Day 1 | |
Secondary | Delis-Kaplan Executive Function System (D-KEF)-Verbal Fluency Performance: Cold Cognitive Function Testing | Cold cognitive function will be measured by D-KEFs Verbal Fluency Test, made up of letter fluency and category fluency, is measured by number of responses, a larger number represents a better outcome. | Day 1 | |
Secondary | MEG: Magnetoencephalography | Six minutes, eyes-open resting-state scan and eighteen minutes of task-based scan will be completed. Participants will be inside the MEG scanner room for 25-30 minutes. Before the scan, five coils will be secured to the participant's head and 3D digitizer will be used to map the location of the coils, fiducials, and scalp surface, MEG data will be co-registered to their high-resolution structural T1-weighted MRI. This will provide a four-dimensional (4D) image of brain activity, similar to Functional magnetic resonance imaging (fMRI). | Baseline Day1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00316160 -
Sexual Functioning Study With Antidepressants
|
Phase 4 | |
Completed |
NCT05416957 -
Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
|
Phase 1 | |
Active, not recruiting |
NCT03642964 -
A Study in Patients With Major Depressive Disorder
|
Phase 2 | |
Terminated |
NCT01111565 -
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
|
Phase 3 | |
Completed |
NCT01912196 -
Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)
|
Phase 2 | |
Completed |
NCT00958204 -
Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression
|
Phase 3 | |
Completed |
NCT00102492 -
Study Of GW679769 In Major Depressive Disorder
|
Phase 2 | |
Completed |
NCT02012218 -
Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
|
Phase 3 | |
Completed |
NCT01477203 -
Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders
|
Phase 4 | |
Completed |
NCT00768430 -
Optimization of IV Ketamine for Treatment Resistant Depression
|
Phase 2 | |
Completed |
NCT00559299 -
Patient Tolerability Study of GSK163090
|
Phase 1 | |
Terminated |
NCT01123707 -
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
|
Phase 3 | |
Completed |
NCT04403373 -
Effectiveness of Walking Exercise in Improving Depression in Older Adults With Major Depressive Disorder, A Pilot Study
|
N/A | |
Completed |
NCT05541302 -
Retrospective TMS Therapy for Adults With MDD
|
||
Recruiting |
NCT06385405 -
Electroencephalography-based Precise Repetitive Transcranial Magnetic Stimulation Treatment
|
N/A | |
Completed |
NCT00330616 -
Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan
|
Phase 2 | |
Recruiting |
NCT03012724 -
Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)
|
N/A | |
Completed |
NCT02380066 -
Comparison of Anyu Peibo With Placebo in Treatment of MDD
|
Phase 2 | |
Not yet recruiting |
NCT02395263 -
Comparison of Yuxintine With Placebo in Treatment of MDD
|
Phase 2 | |
Completed |
NCT01187407 -
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
|
Phase 3 |